Preferences and utilities for health states after treatment for oropharyngeal cancer: Transoral robotic surgery versus definitive (chemo)radiotherapy

Head and Neck

Volumn 36, Issue 7, 2014, Pages 923-933

  De Almeida, John R ^a   Villanueva, Nathaniel L ^a   Moskowitz, Alan J ^a   Miles, Brett A ^a   Teng, Marita S ^a   Sikora, Andrew ^a   Gupta, Vishal ^a   Posner, Marshall ^a   Genden, Eric M ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

chemoradiotherapy; health states; oropharyngeal cancer; preferences; transoral robotic surgery; utilities

Indexed keywords

ADJUVANT THERAPY; ADULT; AGED; ATTITUDE TO HEALTH; CHEMORADIOTHERAPY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OROPHARYNGEAL NEOPLASMS; PATIENT PREFERENCE; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; ROBOTIC SURGICAL PROCEDURE; TUMOR RECURRENCE; VISUAL ANALOG SCALE; YOUNG ADULT;

ADULT; AGED; ATTITUDE TO HEALTH; CHEMORADIOTHERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OROPHARYNGEAL NEOPLASMS; PATIENT PREFERENCE; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; ROBOTIC SURGICAL PROCEDURES; VISUAL ANALOG SCALE; YOUNG ADULT;

EID: 84902536372     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23340     Document Type: Article

References (37)

1. Dwivedi RC, St Rose S, Chisholm EJ, et al. Evaluation of factors affecting post-treatment quality of life in oral and oropharyngeal cancer patients treated with curative surgery: an exploratory study. Eur Arch Otorhinolaryngol 2012; 269: 591-599.
2. Tribius S, Bergelt C,. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: is there a worthwhile quality of life gain? Cancer Treat Rev 2011; 37: 511-519.
3. Kim TW, Youm HY, Byun H, Som YI, Baek CH,. Treatment outcomes and quality of life in oropharyngeal cancer after surgery-based versus radiation-based treatment. Clin Exp Otorhinolaryngol 2010; 3: 153-160.
4. Mowry SE, Tang C, Sadeghi A, Wang MB,. Standard chemoradiation versus intensity-modulated chemoradiation: a quality of life assessment in oropharyngeal cancer patients. Eur Arch Otorhinolaryngol 2010; 267: 1111-1116.
5. Chang EI, Leon P, Hoffman WY, Schmidt BL,. Quality of life for patients requiring surgical resection and reconstruction for mandibular osteoradionecrosis: 10-year experience at the University of California San Francisco. Head Neck 2012; 34: 207-212.
6. Cheung KK, Leung SF, Liang RH, Tai JW, Yeung RM, Thompson DR,. Oropharyngeal mucositis-specific quality-of-life measure in patients with cancer therapy. Hong Kong Med J 2010; 16 Suppl 3: 42-46.
7. Rose-Ped AM, Bellm LA, Epstein JB, Trotti A, Gwede C, Fuchs HJ,. Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs 2002; 25: 461-467; quiz 468-469.
8. Funk GF, Karnell LH, Christensen AJ,. Long-term health-related quality of life in survivors of head and neck cancer. Arch Otolaryngol Head Neck Surg 2012; 138: 123-133.
9. Boscolo-Rizzo P, Stellin M, Fuson R, Marchiori C, Gava A, Da Mosto MC,. Long-term quality of life after treatment for locally advanced oropharyngeal carcinoma: surgery and postoperative radiotherapy versus concurrent chemoradiation. Oral Oncol 2009; 45: 953-957.
10. Gurney TA, Eisele DW, Orloff LA, Wang SJ,. Predictors of quality of life after treatment for oral cavity and oropharyngeal carcinoma. Otolaryngol Head Neck Surg 2008; 139: 262-267.
11. Goldstein NE, Genden E, Morrison RS,. Palliative care for patients with head and neck cancer: "I would like a quick return to a normal lifestyle." JAMA 2008; 299: 1818-1825.
12. Genden EM, Kotz T, Tong CC, et al. Transoral robotic resection and reconstruction for head and neck cancer. Laryngoscope 2011; 121: 1668-1674.
13. Sinclair CF, McColloch NL, Carroll WR, Rosenthal EL, Desmond RA, Magnuson JS,. Patient-perceived and objective functional outcomes following transoral robotic surgery for early oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2011; 137: 1112-1116.
14. Hurtuk AM, Marcinow A, Agrawal A, Old M, Teknos TN, Ozer E,. Quality-of-life outcomes in transoral robotic surgery. Otolaryngol Head Neck Surg 2012; 146: 68-73.
15. Leonhardt FD, Quon H, Abrahão M, O'Malley BW Jr, Weinstein GS,. Transoral robotic surgery for oropharyngeal carcinoma and its impact on patient-reported quality of life and function. Head Neck 2012; 34: 146-154.
16. Bonastre MJ, Noël E, Bensadoun RJ, et al. [The cost of intensity modulated radiotherapy in head and neck cancers: results of the 2002 STIC study]. [Article in French] Bull Cancer 2006; 93: 1026-1032.
17. Bhayani MK, Holsinger FC, Lai SY,. A shifting paradigm for patients with head and neck cancer: transoral robotic surgery (TORS). Oncology (Williston Park) 2010; 24: 1010-1015.
18. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. 1st ed. New York, NY: Oxford University Press; 1996.
19. Sher DJ, Tishler RB, Annino D, Punglia RS,. Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer. Ann Oncol 2010; 21: 1072-1077.
20. Yen RF, Yen MF, Hong RL, Tzen KY, Chien CR, Chen TH,. The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma. Acad Radiol 2009; 16: 54-60.
21. Parthan A, Posner MR, Brammer C, Beltran P, Jansen JP,. Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck 2009; 31: 1255-1262.
22. Furlong W, Feeny D, Torrance GW, Barr R, Horsman J,. Guide to design and development of health-state utility instrumentation. Hamilton, Ontario: Macmaster University; 1990.
23. Brown RE, Hutton J,. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 1998; 9: 899-907.
24. Kilbridge KL, Weeks JC, Sober AJ, et al. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 2001; 19: 812-823.
25. Chan JL, Kabeto MU, Oldread AE, et al. The use of preferences to measure the benefit of adjuvant radiation therapy for stage I seminoma. Int J Radiat Oncol Biol Phys 2002; 53: 934-941.
26. Cappelli M, Surh L, Humphreys L, et al. Measuring women's preferences for breast cancer treatments and BRCA1/BRAC2 testing. Qual Life Res 2001; 10: 595-607.
27. de Boer AG, Stalmeier PF, Sprangers MA, et al. Transhiatal vs extended thoracic resection in oesophageal carcinoma: patients' utilities and treatment preferences. Br J Cancer 2002; 86: 851-857.
28. Brotherston DC, Poon I, Le T, et al. Patient preferences for oropharyngeal cancer treatment de-escalation. Head Neck 2013; 35: 151-159.
29. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
30. Peres J,. HPV-positive oropharyngeal cancer: data may justify new approach. J Natl Cancer Inst 2010; 102: 1456-1459.
31. Hollenbeak CS, Lowe VJ, Stack BC Jr,. The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck. Cancer 2001; 92: 2341-2348.
32. Wildi SM, Cox MH, Clark LL, et al. Assessment of health state utilities and quality of life in patients with malignant esophageal dysphagia. Am J Gastroenterol 2004; 99: 1044-1049.
33. Froberg DG, Kane RL,. Methodology for measuring health-state preferences-II: scaling methods. J Clin Epidemiol 1989; 42: 459-471.
34. de Haes JC, Stiggelbout AM,. Assessment of values, utilities and preferences in cancer patients. Cancer Treat Rev 1996; 22 Suppl A: 13-26.
35. Stiggelbout AM, Eijkemans MJ, Kiebert GM, Kievit J, Leer JW, De Haes HJ,. The 'utility' of the visual analog scale in medical decision making and technology assessment. Is it an alternative to the time trade-off? Int J Technol Assess Health Care 1996; 12: 291-298.
36. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
37. Wright DR, Wittenberg E, Swan JS, Miksad RA, Prosser LA,. Methods for measuring temporary health states for cost-utility analyses. Pharmacoeconomics 2009; 27: 713-723.